MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals ROA Ratio 2011-2026 | AMPH
Annual ROA Ratio Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.02 | 10.11 | 9.09 | 12.32 | 9.25 | 0.22 | 8.34 | -1.12 | 0.99 | 2.46 | -0.71 | -2.75 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.32 | -2.75 | 4.52 |
Quarterly ROA Ratio Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.13 | 8.71 | 9.33 | 5.16 | 8.35 | 8.92 | 9.74 | 9.92 | 9.92 | 5.76 | 8.16 | 8.18 | 10.32 | 14.85 | 13.62 | 6.48 | 7.1 | 3.19 | 1.99 | 1.22 | 1.04 | 0.64 | 8.82 | 8.34 | 8.88 | 9.12 | 0.42 | -1.12 | -1.16 | -1.6 | -0.61 | 0.98 | 0.01 | 0.9 | 2.08 | 2.46 | 5.03 | 3.35 | 0.04 | -0.71 | -3.29 | -3.9 | -2.5 | -2.75 | -1.56 | -0.23 | 2.38 | 2.8 | 2.26 | 2.31 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.85 | -3.9 | 4.01 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
-44.67 | $ 3.02 | 1.0 % | $ 258 M |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
65.02 | $ 90.9 | -0.31 % | $ 27.2 B | Germany |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Codexis
CDXS
|
-29.75 | $ 1.93 | 6.04 % | $ 168 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.9 | 1.88 % | $ 362 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Cullinan Management
CGEM
|
-49.04 | $ 15.2 | 5.34 % | $ 916 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.69 | -2.31 % | $ 198 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-88.77 | $ 0.46 | -13.46 % | $ 5.27 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-183.81 | $ 2.27 | 0.39 % | $ 1.01 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 8.3 | 3.36 % | $ 227 M | Israel |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-46.69 | $ 10.37 | 1.97 % | $ 138 M | USA |
 |
Cardiff Oncology
CRDF
|
-74.09 | $ 1.6 | 0.95 % | $ 107 M | USA |
 |
Curis
CRIS
|
-37.97 | $ 0.53 | -3.64 % | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.32 | $ 38.09 | 2.31 % | $ 3.58 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 49.43 | -0.17 % | $ 4.44 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
CytomX Therapeutics
CTMX
|
-11.46 | $ 4.41 | -3.4 % | $ 608 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-33.8 | $ 0.87 | 1.26 % | $ 5.85 M | USA |
 |
Cue Biopharma
CUE
|
-63.02 | $ 0.17 | -7.12 % | $ 16.1 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.43 | 1.18 % | $ 2.09 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
-31.93 | $ 4.34 | -29.51 % | $ 10.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |